Overview

A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)

Status:
NOT_YET_RECRUITING

Trial end date:
2030-03-31

Target enrollment:

Participant gender:

Summary

The goal of this clinical trial is to see how well dostarlimab works when administered with the chemotherapy drugs carboplatin and paclitaxelin in treating EC in Chinese participants. The study aims to understand the treatments effectiveness, safety, how the drugs behave in the body, and whether it causes any immune reactions.

Phase:

PHASE2

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Carboplatin
dostarlimab
Paclitaxel